There is a simple discount patient access scheme for elacestrant. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Suggested remit: To appraise the clinical and cost effectiveness of elacestrant within its marketing authorisation for treating postmenopausal hormone receptor-positive HER2-negative advanced or ...

More than a thousand women with advanced breast cancer are set to get ‘more time with loved ones’ after a new treatment was given the go-ahead on the NHS. The once-a-day table, elacestrant ...